However, in more advanced stages such as overt T2DM, this increase is often accompanied by impaired downstream signaling referred to as FGF21 resistance resulting in diminished metabolic and neuroprotective efficacy [71]. The gene discussed is FGF21; the disease is type 2 diabetes mellitus.